Search results
Results from the WOW.Com Content Network
The selloff in ABBV stock was always a bit overdramatic. The pharma has over 90 therapies under development , over half of them being in mid- to late-stage trials. AbbVie spent $12.8 billion on ...
AbbVie Inc. (NYSE:ABBV) shares are trading higher on Friday. The company reported fourth-quarter adjusted earnings per share of $2.16, beating the street view of $2.11. Quarterly sales of $15.102 ...
The contrast between AbbVie's performance and that of the wider market was stark, as the bellwether S&P 500 (SNPINDEX: ^GSPC) sank by a relatively steep 1.5%. Why AbbVie Stock Popped While the ...
Pharmaceutical powerhouse AbbVie (NYSE: ABBV) has been a beast since it spun off from Abbott Laboratories in 2012. Over the past decade, the stock has averaged a dividend yield of 3.5% while ...
For reference, AbbVie's trailing 12-month revenue was $55.3 billion, so the growth of Skyrizi and Rinvoq represents a major addition to the top line that'll likely drive the stock upwards for ...
In the latest trading session, AbbVie (ABBV) closed at $88.50, marking a -0.63% move from the previous day.
AbbVie (ABBV) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
AbbVie (ABBV) closed the most recent trading day at $88.09, moving -1.55% from the previous trading session.